Contact
      Please use this form to send email to PR contact of this press release:
      
      Innorna Receives IND Clearance by FDA Enabling Phase I Initiation for Bivalent Respiratory Syncytial Virus mRNA Vaccine
    
      TO:
      
      bd@innorna.com
      
      Innorna